Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Pharvaris N.V. (PHVS : NSDQ)
 
 • Company Description   
Pharvaris N.V. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema and other bradykinin-B2-receptor-mediated indications. Pharvaris N.V. is based in ZUG, Switzerland.

Number of Employees: 34

 
 • Price / Volume Information   
Yesterday's Closing Price: $16.70 Daily Weekly Monthly
20 Day Moving Average: 33,197 shares
Shares Outstanding: 31.84 (millions)
Market Capitalization: $531.72 (millions)
Beta: -0.42
52 Week High: $22.21
52 Week Low: $13.14
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -4.52% 7.55%
12 Week -3.41% 6.19%
Year To Date 16.05% 41.80%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
J.H. OORTWEG 21 2333 CH LEIDEN
-
LEIDEN,P7 -
NLD
ph: 31-71-203-6410
fax: -
sarah.mccabe@sternir.com http://www.pharvaris.com
 
 • General Corporate Information   
Officers
Berndt Modig - Chief Executive Officer and Executive Director
Jochen Knolle - Chief Scientific Officer and Chief Operating Offic
Anna Nijdam - Head of Finance and Principal Accounting Officer
Hans Schikan - Director
David Meeker - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N69605108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/29/22
Share - Related Items
Shares Outstanding: 31.84
Most Recent Split Date: (:1)
Beta: -0.42
Market Capitalization: $531.72 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.03 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 4.75% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/29/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.48
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 32.50%
vs. Previous Quarter: -14.89%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -24.98
12/31/21 - -19.25
09/30/21 - -
ROA
03/31/22 - -24.05
12/31/21 - -18.60
09/30/21 - -
Current Ratio
03/31/22 - 19.84
12/31/21 - 30.31
09/30/21 - 29.72
Quick Ratio
03/31/22 - 19.84
12/31/21 - 30.31
09/30/21 - 29.72
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 6.73
12/31/21 - 7.62
09/30/21 - 7.98
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.06
12/31/21 - 0.07
09/30/21 - 0.08
 

Powered by Zacks Investment Research ©